Advances on the treatment in neuropathic corneal pain

doi:10.3877/cma.j.issn.2095-2007.2021.02.010

Abstract

Abstract:

Neuropathic corneal pain (NCP) is a special type of pain. Recently, the definition, pathogenesis and diagnostic criteria of NCP have not been clearly defined, which makes the diagnosis and treatment of NCP extremely challenging. In recent years, the novel treatment of NCP has been developed and enriched. This progress of NCP treatment in recent years will be reviewed in this paper, which may be helpful to improve ophthalmologists′ understanding of NCP and promote the application of these methods in the treatment of NCP.

Key words: Neuropathic corneal pain, Treatment, Research progress

Qiankun Chen, Qingfeng Liang. Advances on the treatment in neuropathic corneal pain[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2021, 11(02): 114-118.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2021.02.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2021/V11/I02/114

Figures/Tables 1

References 57

[1]	Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain[J]. Pain, 2011, 152(10): 2204-2205.
[2]	Goyal S, Hamrah P. Understanding neuropathic corneal pain——gaps and current therapeutic approaches[J]. Semin Ophthalmol, 2016, 31(1/2): 59-70.
[3]	Mehra D, Cohen NK, Galor A. Ocular surface pain: a narrative review[J]. Ophthalmol Ther, 2020, 9(3): 1-21.
[4]	Siedlecki AN, Smith SD, Siedlecki AR, et al. Ocular pain response to treatment in dry eye patients[J]. Ocul Surf, 2020，18(2): 305-311.
[5]	Oprée A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin[J]. J Neurosci, 2000, 20(16): 6289-6293.
[6]	Dieckmann G, Goyal S, Hamrah P. Neuropathic corneal pain: approaches for management[J]. Ophthalmology, 2017，124(11): S34-S47.
[7]	Aggarwal S, Kheirkhah A, Cavalcanti BM, et al. Autologous serum tears for treatment of photoallodynia in patients with corneal neuropathy: efficacy and evaluation with in vivo confocal microscopy[J]. Ocul Surf, 2015, 13(3): 250-262.
[8]	Cirillo G, Cavaliere C, Bianco MR, et al. Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain[J]. Cell Mol Neurobiol, 2010, 30(1): 51-62.
[9]	van Velzen M, Heij L, Niesters M, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis[J]. Expert Opin Investig Drugs, 2014, 23(4): 541-550.
[10]	Nettune GR, Pflugfelder SC. Post-LASIK tear dysfunction and dysesthesia[J]. Ocul Surf, 2010, 8(3): 135-145.
[11]	Theophanous C, Jacobs DS, Hamrah P. Corneal neuralgia after LASIK[J]. Optom Vis Sci, 2015, 92(9): e233-e240.
[12]	Aggarwal S, Colon C, Kheirkhah A, et al. Efficacy of autologous serum tears for treatment of neuropathic corneal pain[J]. Ocul Surf, 2019，17(3): 532-539.
[13]	Siedlecki AN, Smith SD, Siedlecki AR, et al. Ocular pain response to treatment in dry eye patients[J]. Ocul Surf, 2020, 18(2): 305-311.
[14]	Moynes DM, Vanner SJ, Lomax AE. Participation of interleukin 17A in neuroimmune interactions[J]. Brain Behav Immun, 2014, 41: 1-9.
[15]	Shaheen BS, Bakir M, Jain S. Corneal nerves in health and disease[J]. Surv Ophthalmol, 2014, 59(3): 263-285.
[16]	de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome[J]. Arq Bras Oftalmol, 2008, 71(6): 89-95.
[17]	Beckman K, Katz J, Majmudar P, et al. Loteprednol etabonate for the treatment of dry eye disease[J]. J Ocul Pharmacol Ther, 2020, 36(7): 497-511.
[18]	Fong R, Leitritz M, Siou-Mermet R, et al. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial[J]. Clin Ophthalmol, 2012, 6: 1113-1124.
[19]	Rajpal RK, Roel L, Siou-Mermet R, et al. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery[J]. J Cataract Refract Surg, 2013, 39(2): 158-167.
[20]	Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen[J]. Cornea, 2009, 28(10): 1091-1096.
[21]	Tong L, Sun CC, Yoon KC, et al. Cyclosporine anionic and cationic ophthalmic emulsions in dry eye disease: a literature review[J]. Ocul Immunol Inflamm, 2020: 1-10.
[22]	Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops[J]. Cornea, 2012, 31(8): 945-949.
[23]	Abidi A, Shukla P, Ahmad A. Lifitegrast: A novel drug for treatment of dry eye disease[J]. J Pharmacol Pharmacother, 2016, 7(4): 194-198.
[24]	Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study[J]. Cornea, 2016, 35(6): 741-748.
[25]	Morkin MI, Hamrah P. Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain[J]. Ocul Surf, 2018, 16(1): 132-138.
[26]	Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? [J]. Ocul Surf, 2004, 2(3): 177-187.
[27]	Ijiri S, Kobayashi A, Sugiyama K, et al. Evaluation of visual acuity and color vision in normal human eyes with a sutureless temporary amniotic membrane patch[J]. Am J Ophthalmol, 2007, 144(6): 938-942.
[28]	Dimit R, Gire A, Pflugfelder SC, et al.Patient ocular conditions and clinical outcomes using a PROSE scleral device[J]. Cont Lens Anterior Eye, 2013, 36(4): 159-163.
[29]	Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease[J]. Cornea, 2007, 26(10): 1195-1199.
[30]	Rosenthal P, Borsook D. The corneal pain system. Part Ⅰ：the missing piece of the dry eye puzzle[J]. Ocul Surf, 2012, 10(1): 2-14.
[31]	Ozmen MC, Dieckmann G, Cox SM, et al. Efficacy and tolerability of nortriptyline in the management of neuropathic corneal pain[J]. Ocul Surf, 2020, 18(4): 814-820.
[32]	Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains[J]. Curr Opin Neurol, 2009, 22(5): 467-474.
[33]	Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain[J]. Eur J Neurol, 2006, 13(11): 1153-1169.
[34]	Pakravan M, Roshani M, Yazdani S, et al.Pregabalin and gabapentin for post-photorefractive keratectomy pain: a randomized controlled trial[J]. Eur J Ophthalmol, 2012, 22(7): S106-S113.
[35]	Small LR, Galor A, Felix ER, et al. Oral gabapentinoids and nerve blocks for the treatment of chronic ocular pain[J]. Eye Contact Lens, 2020, 46(3): 174-181.
[36]	Ozmen MC. Is gabapentin effective in dry eye disease and neuropathic ocular pain? [J]. Acta Neurol Belg, 2020，120(5): 1215-1216.
[37]	Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, crohn′s disease, and other chronic pain disorders[J]. Pharmacotherapy, 2018, 38(3): 382-389.
[38]	Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review[J]. Curr Pain Headache Rep, 2020, 24(10): 64.
[39]	Cruccu G, Garcia-Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions[J]. Eur J Neurol, 2016, 23(10): 1489-1499.
[40]	Abram SE. Neural blockade for neuropathic pain[J]. Clin J Pain, 2000, 16(2): S56-S61.
[41]	Hayek SM, Sweet JA, Miller JP, et al. Successful management of corneal neuropathic pain with intrathecal targeted drug delivery[J]. Pain Med, 2016, 17(7): 1302-1307.
[42]	Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A[J]. Neurotoxicology, 2005, 26(5): 785-793.
[43]	Oh HM, Chung ME. Botulinum toxin for neuropathic pain: a review of the literature[J]. Toxins (Basel), 2015, 7(8): 3127-3154.
[44]	Diel RJ, Hwang J, Kroeger ZA, et al. Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections[J]. Br J Ophthalmol, 2019，103(8): 1024-1029.
[45]	Venkateswaran N, Hwang J, Rong AJ, et al. Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients[J]. Am J Ophthalmol Case Rep, 2020，19: 100809.
[46]	Sivanesan E, Levitt RC, Sarantopoulos CD, et al. Noninvasive electrical stimulation for the treatment of chronic ocular pain and photophobia[J]. Neuromodulation, 2018, 21(8): 727-734.
[47]	Zayan K, Aggarwal S, Felix E, et al. Transcutaneous electrical nerve stimulation for the long-term treatment of ocular pain[J]. Neuromodulation, 2020, 23(6): 871-877.
[48]	Farhangi M, Cheng AM, Baksh B, et al. Effect of non-invasive intranasal neurostimulation on tear volume, dryness and ocular pain[J]. Br J Ophthalmol, 2020, 104(9): 1310-1316.
[49]	Dermer H, Lent-Schochet D, Theotoka D, et al. A review of management strategies for nociceptive and neuropathic ocular surface pain[J]. Drugs, 2020, 80(6): 547-571.
[50]	Kami K, Tajima F, Senba E. Exercise-induced hypoalgesia: potential mechanisms in animal models of neuropathic pain[J]. Anat Sci Int, 2017, 92(1): 79-90.
[51]	Grace PM, Fabisiak TJ, Green-Fulgham SM, et al. Prior voluntary wheel running attenuates neuropathic pain[J]. Pain, 2016, 157(9): 2012-2023.
[52]	Ko GD, Nowacki NB, Arseneau L, et al. Omega-3 fatty acids for neuropathic pain: case series[J]. Clin J Pain, 2010, 26(2): 168-172.
[53]	Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies[J]. Med Sci Monit, 2014, 20: 1583-1589.
[54]	Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG, et al. n-3 fatty acid supplemen-tation for the treatment of dry eye disease[J]. N Engl J Med, 2018, 378(18): 1681-1690.
[55]	Hadjivassiliou M, Grünewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness[J]. J Neurol Neurosurg Psychiatry, 2002, 72(5): 560-563.
[56]	Shetty R, Deshpande K, Ghosh A, et al. Management of ocular neuropathic pain with vitamin B12 supplements: a case report[J]. Cornea, 2015, 34(10): 1324-1325.
[57]	Lamb SE, Hansen Z, Lall R, et al. Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis[J]. Lancet, 2010, 375(9718): 916-923.

第一作者	类型	治疗方法	治疗效果	证据水平
Aggarwal等^[12]	周围敏化	自体血清	眼痛程度从(9.1±0.2)分减轻至(3.1±0.3)分	3
Fong等^[18]		局部皮质类固醇(如0.5%氯替泼诺)	白内障术后18 d无眼痛患者氯替泼诺组和照组分别为73.3%和39.3%	1
Theophanous等^[11]		绷带镜和巩膜镜	自体血清联合绷带镜治疗眼痛减轻50%	5
Ozmen等^[31]	中枢敏化和(或)周围敏化	三环类抗抑郁药(去甲替林)	40%患者眼痛减轻>50%，20%患者减轻30%~49%	3
Small等^[35]		抗癫痫药(加巴喷丁和普瑞巴林)	25%患者眼痛完全缓解，37.5%患者显著缓解	4
Farhangi等^[48]	顽固性NCP	非侵入性鼻内神经刺激	37%患者眼痛减轻≥50%，43%患者眼痛减轻≥30%	4
Shetty等^[56]	其他疗法	补充维生素B12	3周后眼部症状完全消失	5

第一作者	类型	治疗方法	治疗效果	证据水平
Aggarwal等^[12]	周围敏化	自体血清	眼痛程度从(9.1±0.2)分减轻至(3.1±0.3)分	3
Fong等^[18]		局部皮质类固醇(如0.5%氯替泼诺)	白内障术后18 d无眼痛患者氯替泼诺组和照组分别为73.3%和39.3%	1
Theophanous等^[11]		绷带镜和巩膜镜	自体血清联合绷带镜治疗眼痛减轻50%	5
Ozmen等^[31]	中枢敏化和(或)周围敏化	三环类抗抑郁药(去甲替林)	40%患者眼痛减轻>50%，20%患者减轻30%~49%	3
Small等^[35]		抗癫痫药(加巴喷丁和普瑞巴林)	25%患者眼痛完全缓解，37.5%患者显著缓解	4
Farhangi等^[48]	顽固性NCP	非侵入性鼻内神经刺激	37%患者眼痛减轻≥50%，43%患者眼痛减轻≥30%	4
Shetty等^[56]	其他疗法	补充维生素B12	3周后眼部症状完全消失	5

Please choose a citation manager

Content to export